- Home
- AGAE vs SCNX Comparison
AGAE vs SCNX Comparison
Compare AGAE & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- SCNX
- Stock Information
- Founded
- AGAE 2017
- SCNX 2010
- Country
- AGAE United States
- SCNX United States
- Employees
- AGAE N/A
- SCNX N/A
- Industry
- AGAE Cable & Other Pay Television Services
- SCNX Other Pharmaceuticals
- Sector
- AGAE Telecommunications
- SCNX Health Care
- Exchange
- AGAE Nasdaq
- SCNX Nasdaq
- Market Cap
- AGAE 38.8M
- SCNX 33.6M
- IPO Year
- AGAE N/A
- SCNX 2020
- Fundamental
- Price
- AGAE $1.39
- SCNX $0.92
- Analyst Decision
- AGAE
- SCNX
- Analyst Count
- AGAE 0
- SCNX 0
- Target Price
- AGAE N/A
- SCNX N/A
- AVG Volume (30 Days)
- AGAE 101.6K
- SCNX 84.6K
- Earning Date
- AGAE 05-19-2025
- SCNX 05-23-2025
- Dividend Yield
- AGAE N/A
- SCNX N/A
- EPS Growth
- AGAE N/A
- SCNX N/A
- EPS
- AGAE N/A
- SCNX 2.68
- Revenue
- AGAE $9,256,023.00
- SCNX $136,643.00
- Revenue This Year
- AGAE N/A
- SCNX N/A
- Revenue Next Year
- AGAE N/A
- SCNX N/A
- P/E Ratio
- AGAE N/A
- SCNX $1.25
- Revenue Growth
- AGAE 36.15
- SCNX N/A
- 52 Week Low
- AGAE $0.61
- SCNX $0.69
- 52 Week High
- AGAE $1.57
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- AGAE 67.69
- SCNX N/A
- Support Level
- AGAE $1.26
- SCNX N/A
- Resistance Level
- AGAE $1.50
- SCNX N/A
- Average True Range (ATR)
- AGAE 0.13
- SCNX 0.00
- MACD
- AGAE 0.03
- SCNX 0.00
- Stochastic Oscillator
- AGAE 80.07
- SCNX 0.00
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.